Archives 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 October 02, 2014 INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2014 Read More October 02, 2014 Lupuzor™ Gears Up To Start Pivotal Phase III trials Read More June 27, 2014 ANNUAL GENERAL MEETING: 2014 Read More June 27, 2014 ImmuPharma to access pioneering research in the Bordeaux region of France Read More June 16, 2014 New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency Read More June 09, 2014 PRELIMINARY RESULTS 2013: a year of substantial progress for the year ended 31 December 2013 Read More May 23, 2014 Annual Report and Accounts Notice of Annual General Meeting: 27 June 2014 Read More May 06, 2014 Dr. Sylviane Muller – Presentation Abstract from 2014 European Lupus Conference Read More April 23, 2014 Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan Read More April 11, 2014 ImmuPharma Sponsors the 2014 European Lupus Conference Read More August 13, 2013 UPDATE: Cancer Programme IPP-204106 Read More August 12, 2013 FDA Grants ImmuPharma ammended SPA for Lupuzor Phase III; Company Progresses Development Activities Read More 1…1314151617
June 16, 2014 New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency Read More
June 09, 2014 PRELIMINARY RESULTS 2013: a year of substantial progress for the year ended 31 December 2013 Read More
May 06, 2014 Dr. Sylviane Muller – Presentation Abstract from 2014 European Lupus Conference Read More
April 23, 2014 Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan Read More
August 12, 2013 FDA Grants ImmuPharma ammended SPA for Lupuzor Phase III; Company Progresses Development Activities Read More
